Gout is the most common inflammatory arthritis affecting 1-2% of the population. It is a very common problem presenting to ...

Weight-loss injections such as Ozempic and Wegovy are helping millions lose weight quickly. But could rapid weight loss affect bone strength and increase gout risk?

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

Between, bunions, corns and crooked toes, our feet may not win any beauty awards but, with 26 bones, 33 joints, over 100 muscles, tendons and ligaments in each foot, it’s little wonder that feet are ...

In case you've faced some hurdles solving the clue, Toenail treatment, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure time, and test ...

Please provide your email address to receive an email when new articles are posted on . Urate-lowering treatment reduced the 5-year risk for major adverse cardiovascular events for patients with gout.

A groundbreaking new study, led by experts at the University of Nottingham, has found that medicines used to treat gout can also reduce the risk of heart attack and stroke in people with gout. The new ...

Racial disparities in gout and gout treatment are an ongoing but tractable problem, research at the 2025 American College of Rheumatology (ACR)'s annual meeting suggested. In a 10-year ...

In case you've faced some hurdles solving the clue, Toenail treatment, for short, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure time, ...

Gout, the most common form of inflammatory arthritis, often coexists with comorbidities that require integrated assessment and treatment. The burden of cardiovascular-kidney-metabolic (CKM) ...

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...

Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory STOCKHOLM, Dec. 13, ...